39th Annual Feldman Lecture

October 18, 2024 | IN-PERSON EVENT

Delta Hotels – Edmonton South Conference Center

Top of the Inn, 4404 Gateway Boulevard NW, Edmonton AB

Professor Oliver Howes
BM, BCh, MA, MRCPsych, PhD, DM, FMedSci

Schizophrenia: From Molecule to Management

RegisterLearn More

Dr. Oliver Howes is a Professor of Molecular Psychiatry at King’s and Imperial Colleges, London, UK and Head of the Department of Psychosis Studies. He is also Consultant Psychiatrist at the Maudsley Hospital, where he runs a clinical service for people experiencing psychosis symptoms.

His past industry experience includes a period as Vice President for Translational Neuropsychiatry at Lundbeck A/S.

His research interests centre on the cause and treatment of psychosis. His recent work has focused on understanding the role of dopamine, GABA, glutamate, and neuroinflammation in the development of psychosis, the effects of antipsychotic drugs on the nervous and endocrine systems, along with the causes of cognitive impairment in schizophrenia.

He has published over 400 scientific papers, and his work has been recognised through a number of awards including the American College of Neuropsychopharmacology Award for Translational Research (2022), Royal College of Psychiatrists Researcher of the Year Award (2017), Schizophrenia International Research Society Rising Star Award (2013), European Psychiatric Association Biological Psychiatry Prize (2012), and the Royal Society of Medicine Psychiatry Prize (2010). The Web of Science named him one of the most influential researchers in the world over the last decade. He was elected as a Fellow of the Academy of Medical Sciences in 2020.

Plenary Sessions:

Plenary 1

Examining the Biological Clues for the Treatment of Schizophrenia: Why D2 blockers Don’t Work

In this talk, Professor Howes will classify the biological basis of psychotic symptoms and describe how current treatments work to address them. He will distinguish the biological pathways underlying treatment non-response.

Plenary 2

Top Tips for Addressing Antipsychotic Treatment Resistance

Professor Howes will demonstrate a systematic evaluation of non-response in clinical practice incorporating how to rule out pseudo treatment-resistance and address the role of clozapine in optimizing treatment.

Plenary 3

Novel Treatment Approaches: Looking Beyond the D2 Blockers and Clozapine

Professor Howes will describe the potential role of trace amine receptors, introduce muscarinic strategies to target schizophrenia and explain where new approaches will fit into a treatment pathway.


“Schizophrenia is a leading cause of global disability. A better understanding of the aetiology of the disease will aid the development of alternative therapeutic approaches.”

Overall Learning Objectives

Upon completion of this conference, participants should be able to: 

  • Summarize the biological basis for current treatments and why they fail. 
  • Demonstrate a systematic approach to treatment that optimizes outcomes.
  • Describe new approaches to treatment and where they fit into the treatment pathway.


This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. You may claim a maximum of 3.5 hours (credits are automatically calculated).


Friday, October 18, 2024
8:00 am Mountain Time
In-person Event
Delta Hotel – Edmonton South Conference Centre

Time Event
08:00 – 09:00 Registration and Continental Breakfast
09:00 – 09:10 Tribute to Zane Feldman
Welcome and Introduction of Professor Oliver Howes
09:10 – 10:00 Plenary 1 – Examining the Biological Clues for the Treatment of Schizophrenia: Why D2 Blockers Don’t Work
10:00 – 10:20 Question and Answer Period
10:20 – 10:50 Health Break
10:50 – 11:40 Plenary 2 – Top Tips for Addressing Antipsychotic Treatment Resistance
11:40 – 12:00 Question and Answer Period
12:00 – 13:15 Lunch
13:15 – 14:05 Plenary 3 – Novel Treatment Approaches: Looking Beyond D2 Blockers and Clozapine
14:05 – 14:25 Question and Answer Period
14:25 Closing Remarks

Zane Feldman

Zane Feldman made a significant donation to the Department of Psychiatry at the Edmonton General Hospital (now the Grey Nuns Community Hospital) in 1981 in gratitude for the care extended to his two sons. This donation created The Feldman Lectures which began in 1983.

Mr. Feldman was born in Winnipeg in 1923, the son of Israel and Rose (Frank) Feldman. He served in the RCAF and moved to Edmonton in 1949. He had a taxi business before becoming a partner in Crosstown Motor City and later President of West Edmonton Chrysler. Active in the sports community, Zane Feldman was President of the Edmonton Oil Kings and founder and governor of the original Edmonton Oilers in the WHA. He was a director of the Alberta Cancer Board for two years and played a key role in the acquisition of the land for the new Beth Israel Synagogue in West Edmonton. He was the recipient of the Order of Canada Medal in 1992 and was the Negev Dinner honoree in 1993.  Mr. Feldman died in 2003 at the age of 80.

Past Feldman Lecture Distinguished Presenters


Dr. Paul E. Garfinkel, M.D., F.R.C.P. (C)

Professor and Vice Chairman, Department of Psychiatry, University of Toronto
"Selecting an Antidepressant"


Dr. Heinz Lehmann

Professor Emeritus, Department of Psychiatry
McGill University Montreal
"Schizophrenia - Psychiatry's Evergrowing Problem"


Dr. David Sheehan

University of South Florida, Tampa, Florida
"The Anxiety Disease", "The Biology of Panic"

Dr. Hagop S. Akiskal, M.D.

Professor of Psychiatry, The University of Tennessee, Memphis
"Interaction of Psychologic and Biologic factors in the Origin of Mood Disorders", 
"The Soft Bipolar Spectrum - Clinical and Social Significance"




Dr. Harold Mersky

Professor of Psychiatry, University of Western Ontario, Director of Education and Research, London Psychiatric Hospital

"The Idea of Hysteria" "Pain and Compensation" "An individual Perspective on the abuses of Psychiatry in the USSR" "Psychological aspects of Pain"

Professor Sir Martin Roth

University of Cambridge, Department of Psychiatry, Adenbrooke's Hospital, Cambridge, England

"Some Contemporary Growing Points in the Study of Alzheimer's Disease" "Travelling Between Doubt and Certainty in Medicine and Elsewhere" "Use and Abuse of Benzodiazepines"

Norman E. Rosenthal, M.D.

Chief, Unit of Outpatient Studies, Clinical Psychobiology Branch, National Institute of Mental Health, Bethesda, Maryland

"Epidemiologic and Seasonal Changes in the General Population" " What We Know about the Physiological Underpinnings of Seasonal Changes" "Diagnosis of SAD and all its Variants" "Treatment of Seasonal Affective Disorder - Light and Beyond"

Dr. Marie Asberg

Karolinska Institute, Department of Psychiatry and Psychology, Karolinska Hospital, Stockholm, Sweden

"Psychobiology and suicide - can we close the gap between Psychodynamic and Biological Models?"

Dr. Bessel A. van der Kolk

Chief, Erich Linderman Mental Health Centre Trauma Clinic, Massachusetts General Hospital, Harvard Medical School

"Dissociation, Trauma and Psychiatric Illness"

Dr. C.B. Nemeroff

Head, Department of Psychiatry & Behavioural Sciences, Emory University, Atlanta, Georgia

The Biology, Diagnosis & Treatment of Affective Disorder

Dr. Robert M. Post

Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland

Affective Disorders

Dr. Sheldon Preskorn

Department of Psychiatry, University of Kansas School of Medicine, Psychiatric Research Institute, St. Francis Regional Medical Centre
Wichita, Kansas

Update on Antidepressants

Dr. Philip Seeman

Department of Psychiatry, University of Toronto

Schizophrenia and dopamine receptors; Atypical antipsychotic drugs; Future Research and medications

Dr. Norman Sartorius

President, World Psychiatric Association
Head, Mental Health Division, WHO (1997-1993)

“Mental Health and Primary Health Care”, “The Current State of Psychiatry”, “Comorbidity in Psychiatry”

Dr. Glen Gabbard

Bessie Walker Callaway Distinguished Professor of Psychoanalysis and Education, Karl Menninger School of Psychiatry and Mental Health Sciences. The Menninger Clinic, Topeka, Kansas

“Psychodynamic Therapy in a Era of Neuroscience”
“Treatment of Depression Comorbid with Personality Disorders”
“Psychotherapy of the Chronically Suicidal Borderline Patient”

Dr. Michael F. Myers

Clinical Professor, Faculty of Medicine, UBC
St. Paul’s Hospital, Vancouver, B.C.

“Mental Health in Physicians and Allied Professionals”

Dr. Heidi L. Heard

Behavioural Technology Training Group, University of Washington
Behavioral Research and Therapy Clinics, Department of Psychology Seattle, WA

“Dialectical Behaviour Therapy”

Dr. Harold Sackheim

Chief, Department of Biological Psychiatry New York State Psychiatric Institute
New York

“Update on Electroconvulsive Therapy”

Dr. Shitij Kapur

Chief, Department of Biological Psychiatry
New York State Psychiatric Institute, New York

“Linking biology, phenomenology, and Pharmacology in Schizophrenia”

Dr. Roger D. Weiss

Associate Professor of Psychiatry, Harvard Medical School, Clinical Director, Alcohol and Drug Abuse, Program, McLean Hospital

"Treatment Strategies for Patients with Substance Abuse and Dual Diagnosis"

Lt.-Gen. Romeo Dallaire

Meritorious Service Cross, Commander of the 1st Canadian Divisiono, Deputy-Commander of the Canadian Army.

“A Personal Experience with PTSD”

Dr. John W. Newcomer

Professor of Psychiatry and Medicine at Washington University School of Medicine in St. Louis. Medical Director for the Center for Clinical Studies at Washington University

“Atypical Antipsychotics: Metabolic Effects”

Christine A. Padesky, PhD

Distinguished Founding Fellow, Academy of Cognitive Therapy, Co-Founder Center for Cognitive Therapy

“A New Paradigm for Cognitive Therapy of Personality Disorders”

Arthur Caplan, PhD

Emanuel & Robert Hart Professor of Bioethics, Chair of the Department of Medical Ethics and the Director of the Centre for Bioethics at the University of Pennsylvania – Philadelphia

“Is it Ethical to seek to enhance ourselves and our children using biomedical knowledge?”

Dr. Kenneth Kendler

Director, Virginia Institute for Psychiatric and Behavioral Genetics.

“Psychiatric Genetics: A Current Perspective”.

Dr. Martin Seligman

Fox Leadership Professor at the University of Pennsylvania,, Philadelphia, Pennsylvania.

“The Nature & Science of Happiness”

Dr. Arya Sharma

Professor of Medicine & Chair for Cardiovascular Obesity Research and Management, University of Alberta

"Obesity – Assessment & Treatment"

Stephen Michael Stahl, M.D., Ph.D.

Department Of Psychiatry, University Of California – San Diego

“Neuropsychopharmacology of Atypicals”

Baroness Susan Greenfield B.A. (Hons); M.A.; D. Phil

Oxford University, United Kingdom

"Are Digital Technologies Impacting on Wellness of Young Minds”

Kay Redfield Jamieson, PhD

Professor of Medicine, Johns Hopkins University School of Medicine Baltimore, Maryland
"An Overview of Mood Disorders & Suicide"

Jeffrey Lieberman, MD

Lawrence C. Kolb Professor & Chairman, Psychiatry, Columbia University Medical Centre - New York
"Schizophrenia: Past, Present & Future"
"Shrinks - The Untold Story of Psychiatry"

David Nutt, MD

Edmond J. Safra Chair, Psychopharmacology Imperial College, London, England
"Research of Drugs that Affect the Brain & Conditions such as: Addictions, Anxiety & Sleep"

Philip Cowen, BSc, MB, BS, MD, FRCPSYCH

Professor, Psychopharmacology - University of Oxford, Oxford, England, United Kingdom
Classification of Depression & Implications for Treatment

Laurence J. Kirmayer, MD FRCPC FCAHS, FRSC

James McGill Professor & Director, Division of Social & Transcultural Psychiatry, McGill University - Montreal, Quebec
"Integrating Culture & Context in Theory & Practice in Psychiatry"

Dr. Judy Cameron, PhD. University of Pittsburg
Dr. George Koob PhD. Bethesda, MD
Dr. Stephanie Covington PhD, LCWS, La Jolla, California

"The Brain Story"

Professor Mark Edwards MBBS, BSc (Hons), PhD, FRCP, FEAN

King’s College, London, UK
“Functional Neurological Disorders”

Professor Anna Lemke MD

Stanford University School of Medicine
“Dopamine Nation: Finding Balance in the Age of Indulgence”